MDGL, the stock of Madrigal Pharmaceuticals, has been showing signs of a bullish pattern since March 14, 2023. A Broadening Bottom pattern has emerged, which is a bullish reversal pattern. This pattern indicates that the stock has been undergoing increased volatility, with wider price swings, but is ultimately trending upwards.
This pattern was confirmed on April 24, 2023, when the stock broke out of the pattern's resistance level. The breakout was accompanied by strong volume, indicating that there was significant buying pressure, which is a positive sign for investors.
The current confidence level to reach the target price of 369.58 USD is 90%. This means that there is a high likelihood that the stock will reach this level in the near future. The distance to the target price is currently 21%, which represents a significant upside potential.
Investors who want to capitalize on this bullish pattern can consider the breakout price of 307.08 USD as an entry point. This is the price level at which the stock broke out of the pattern's resistance level and is therefore considered a strong buy signal.
The target (exit) price of 369.58 USD represents a potential gain of 20.3% from the breakout price. This is a significant return on investment and represents a good opportunity for investors who are looking to enter the market.
The Broadening Bottom pattern that has emerged in MDGL is a bullish reversal pattern that indicates the stock is trending upwards. The breakout of the pattern's resistance level on April 24, 2023, accompanied by strong volume, confirms this bullish trend. The current confidence level to reach the target price of 369.58 USD is high, and the distance to the target price represents a significant upside potential. Investors who are looking to capitalize on this trend can consider the breakout price of 307.08 USD as an entry point and set a target (exit) price of 369.58 USD.
MDGL saw its Momentum Indicator move below the 0 level on September 12, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In of the 94 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for MDGL moved out of overbought territory on September 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on September 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 50-day moving average for MDGL moved above the 200-day moving average on August 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 155 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.369) is normal, around the industry mean (20.607). P/E Ratio (0.000) is within average values for comparable stocks, (53.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.160). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (17.825) is also within normal values, averaging (333.412).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology